NGS Market Size, Share, Growth, and Industry Analysis, By Type (NovaSeq,NextSeq,Sequel,NanoporeS), By Application (Academic Institutes & Research Centers,Hospitals & Clinics,Pharmaceutical & Biotechnology Companies,Others), Regional Insights and Forecast to 2035

NGS Market Overview

The global NGS Market is forecast to expand from USD 9358.41 million in 2026 and is expected to reach USD 28062.96 million by 2035, growing at a CAGR of 12.98% over the forecast period.

The NGS Market is expanding rapidly as genomic research, precision medicine, oncology profiling, rare-disease investigation, infectious-disease surveillance, drug discovery, and population-scale sequencing generate demand for higher throughput and more flexible sequencing workflows. Approximately 82% of current purchasing activity is influenced by sequencing accuracy, throughput, read length, sample flexibility, turnaround time, bioinformatics compatibility, automation, or cost efficiency per experiment. NovaSeq remains the leading supplied product type because high-throughput laboratories require large-scale sequencing for whole genomes, multiomics, population studies, and extensive research cohorts. NextSeq supports mid-throughput workflows, while Sequel and Nanopore contribute long-read capabilities for structural variation, transcriptomics, assembly, and complex genomic analysis. Academic Institutes & Research Centers remain the leading supplied application because they conduct large volumes of discovery-focused sequencing across human health, agriculture, microbiology, and basic genomics.

The USA remains one of the most important NGS Market environments because of extensive biomedical research funding, advanced cancer genomics, pharmaceutical innovation, clinical laboratory infrastructure, large academic sequencing centers, and growing use of genomic testing. Approximately 78% of major US sequencing programs emphasize higher accuracy, reduced turnaround time, scalable throughput, automated sample preparation, cloud-compatible analysis, long-read integration, or multiomics capability. Academic Institutes & Research Centers operate large sequencing programs, while Hospitals & Clinics increasingly adopt NGS for oncology, hereditary disorders, and other clinically relevant genomic investigations. Pharmaceutical & Biotechnology Companies also expand sequencing use across biomarker discovery, patient stratification, target validation, cell and gene therapy research, and translational development.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Expanding precision medicine and genomic research support market growth, with approximately 70% of sequencing demand influenced by oncology, rare diseases, population genomics, infectious-disease surveillance, pharmacogenomics, or biomarker discovery.
• Major Market Restraint: Bioinformatics complexity and total workflow cost remain important restraints, with approximately 29% of users identifying data interpretation, storage, skilled personnel, validation, computational infrastructure, or workflow standardization as significant challenges.
• Emerging Trends: Long-read sequencing and higher-accuracy high-throughput platforms are reshaping NGS development, with approximately 59% of innovation activity emphasizing longer reads, improved base accuracy, structural-variant detection, multiomics, workflow flexibility, or faster sequencing.
• Regional Leadership: North America is expected to lead the NGS Market with approximately 40% share, supported by biomedical research, clinical genomics, pharmaceutical development, sequencing infrastructure, academic funding, and precision-medicine programs.
• Competitive Landscape: Leading sequencing companies are expanding platform capabilities and workflow flexibility, with approximately 43% of strategic initiatives focused on higher output, improved accuracy, automation, long-read capability, new consumables, or integrated informatics.
• Market Segmentation: NovaSeq leads supplied product types with approximately 39% share, while Academic Institutes & Research Centers dominates supplied applications with approximately 38% because of population genomics, basic research, multiomics, and translational studies.
• Recent Development: NGS platform development accelerated during 2025-2026, with selected programs integrating at least 4 improvements including higher output, faster sequencing, improved accuracy, and more flexible run configurations.

Latest Trends

Long-read sequencing and higher-accuracy high-throughput platforms are becoming central trends across the NGS Market as researchers seek better resolution of structural variation, repetitive regions, haplotypes, transcript isoforms, methylation, and complex genomic architecture. Approximately 59% of innovation activity emphasizes longer reads, improved base accuracy, structural-variant detection, multiomics, workflow flexibility, or faster sequencing. NovaSeq continues evolving toward greater output and more flexible batching, while Sequel and Nanopore technologies strengthen long-read applications where conventional short-read approaches provide incomplete resolution. Academic Institutes & Research Centers increasingly combine short- and long-read sequencing within complementary workflows rather than treating the technologies as direct substitutes.

Automation, flexible run configuration, and integrated informatics represent another major trend as laboratories seek to process more samples without expanding manual workload proportionately. Approximately 62% of advanced NGS development activity focuses on automated library preparation, flexible flow-cell options, streamlined analysis, cloud computing, faster turnaround, or simplified data interpretation. Hospitals & Clinics particularly value standardized workflows because clinical laboratories require reproducibility and predictable turnaround. Pharmaceutical & Biotechnology Companies increasingly integrate sequencing directly into translational and biomarker pipelines, while high-throughput research centers use staggered runs and flexible batching to improve instrument utilization across studies with different sample volumes.

Market Dynamics

Driver

"Precision medicine and expanding genomic research continue to accelerate sequencing demand."

Expanding precision medicine and genomic research remain the strongest drivers of the NGS Market because sequencing increasingly supports oncology, rare-disease investigation, infectious diseases, reproductive genetics, pharmacogenomics, and population research. Approximately 70% of sequencing demand is influenced by oncology, rare diseases, population genomics, infectious-disease surveillance, pharmacogenomics, or biomarker discovery. Hospitals & Clinics increasingly use NGS to characterize clinically relevant genomic alterations, while Academic Institutes & Research Centers conduct large discovery programs across human and non-human biology. Pharmaceutical & Biotechnology Companies rely on sequencing to identify biomarkers, characterize therapeutic responses, and support target discovery throughout research pipelines.

Improving sequencing throughput provides an additional market driver because laboratories can analyze larger cohorts while generating more comprehensive genomic information per run. Approximately 66% of high-throughput implementation programs emphasize whole-genome sequencing, multiomics, cohort expansion, higher sample density, faster turnaround, or lower processing burden. NovaSeq remains particularly relevant for large projects because high-output systems can support extensive research cohorts, while NextSeq offers flexibility for laboratories processing smaller batches. Sequel and Nanopore expand analysis of complex genomic regions where longer reads provide additional biological information.

Restraint

"Data complexity and workflow costs can limit broader sequencing adoption."

Bioinformatics complexity and total workflow cost remain important restraints because generating sequence data is only one component of an NGS program. Approximately 29% of users identify data interpretation, storage, skilled personnel, validation, computational infrastructure, or workflow standardization as significant challenges. Academic Institutes & Research Centers may generate very large datasets that require sustained computing resources, while Hospitals & Clinics need validated analysis pipelines capable of converting sequence information into clinically understandable results. Smaller laboratories can therefore face adoption barriers even when instrument access improves.

Data management creates another restraint because higher-throughput sequencing and multiomics rapidly increase storage, transfer, and analysis requirements. Approximately 34% of operational concerns involve cloud costs, data archiving, cybersecurity, pipeline maintenance, computing performance, or reproducible analysis. NovaSeq-scale output can place substantial demands on informatics infrastructure, while long-read technologies create different analytical requirements around assembly, variant calling, and methylation analysis. Laboratories increasingly evaluate sequencing platforms together with computing capacity rather than as isolated instruments.

Opportunity

"Clinical genomics and long-read applications create substantial opportunities for sequencing expansion."

Clinical genomics creates a major opportunity as Hospitals & Clinics increasingly incorporate NGS into oncology, hereditary-disease, and other genomic testing workflows. Approximately 56% of emerging market opportunities are associated with tumor profiling, inherited disorders, rare diseases, liquid biopsy research, pharmacogenomics, or genomic decision support. Sequencing adoption can expand further as automated workflows and improved analysis reduce operational complexity. High-accuracy platforms are particularly important where laboratories require confidence in clinically relevant variants and standardized reporting.

Long-read sequencing creates another opportunity because researchers increasingly require better characterization of structural variants, repetitive DNA, transcript isoforms, haplotypes, and complete genomic assemblies. Approximately 53% of emerging research opportunities involve structural variation, de novo assembly, transcriptomics, methylation analysis, complex genomic regions, or full-length sequencing. Sequel and Nanopore are particularly relevant to these applications, while integrated studies increasingly combine their long-read strengths with high-throughput short-read data from NovaSeq or NextSeq.

Challenge

"Converting massive sequencing datasets into consistent biological insight remains technically demanding."

Accurate interpretation remains a major technical challenge because sequencing workflows can detect extremely large numbers of genomic differences, only a subset of which may be biologically or clinically meaningful. Approximately 45% of technical-development activity focuses on variant interpretation, algorithm performance, reference databases, annotation consistency, quality control, or analytical reproducibility. Hospitals & Clinics face particularly demanding requirements because clinically relevant findings must be interpreted within validated workflows. Research centers also need reliable analytical methods when integrating genomic data across large cohorts or multiple sequencing platforms.

Standardizing performance across different sequencing technologies creates another challenge because NovaSeq, NextSeq, Sequel, and Nanopore have different read structures, throughput profiles, error characteristics, and workflow requirements. Approximately 40% of platform-integration activity emphasizes cross-platform validation, library compatibility, benchmark datasets, quality metrics, workflow harmonization, or data integration. Laboratories increasingly combine technologies to obtain complementary biological information, but doing so requires careful experimental design and informatics capable of integrating heterogeneous datasets.

Segmentation Analysis

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Types

NovaSeq: NovaSeq leads supplied product types with approximately 39% market share because high-throughput sequencing is central to population genomics, whole-genome sequencing, large oncology studies, multiomics, and extensive research cohorts. Academic Institutes & Research Centers and Pharmaceutical & Biotechnology Companies increasingly require platforms that can process large sample volumes while improving per-sample efficiency. Flexible run configurations also strengthen utilization across studies with different batching requirements.

Approximately 75% of NovaSeq development activity focuses on greater read output, higher base accuracy, faster run times, flexible flow-cell configurations, longer read options, and multiomics support. Platform improvements increasingly target both throughput and scheduling efficiency so laboratories can reduce idle capacity. High-volume sequencing centers particularly benefit from staggered or more flexible run management because multiple projects can have different sample readiness timelines.

NextSeq: NextSeq accounts for approximately 27% of product-type market share and remains important for laboratories requiring substantial sequencing capability without the highest throughput associated with NovaSeq. Hospitals & Clinics, Academic Institutes & Research Centers, and smaller genomic laboratories use NextSeq-class systems across targeted sequencing, transcriptomics, oncology research, and flexible mid-throughput workflows. The platform category provides a practical balance between capacity and manageable batch sizes.

Approximately 68% of NextSeq development activity emphasizes workflow automation, faster sequencing, simplified operation, flexible batching, integrated informatics, and broader assay compatibility. Laboratories increasingly value mid-throughput systems that can support multiple applications without requiring extremely large sample cohorts for efficient operation. Automated workflows also make these systems attractive where technical staffing is limited.

Sequel: Sequel represents approximately 18% of product-type market share and serves long-read sequencing applications where genomic continuity and high-fidelity sequence information are especially valuable. Academic Institutes & Research Centers use the technology for genome assembly, structural variation, transcriptomics, haplotyping, and complex genomic regions. Pharmaceutical & Biotechnology Companies also apply long-read sequencing to characterize biologically important variation that may be difficult to resolve with short reads alone.

Approximately 64% of Sequel development activity focuses on read accuracy, long-fragment sequencing, structural-variant detection, full-length transcript analysis, workflow throughput, and complex genome characterization. Increasing high-fidelity performance strengthens the technology's relevance where both read length and sequence accuracy are required. Researchers increasingly combine these data with short-read sequencing for more comprehensive genomic analysis.

Nanopore: Nanopore accounts for approximately 16% of product-type market share and benefits from real-time sequencing, flexible device formats, long reads, direct nucleic-acid analysis, and deployment across laboratories with different throughput requirements. Academic Institutes & Research Centers use Nanopore for genome assembly, pathogen investigation, field sequencing, transcript analysis, and methylation research. Its flexible hardware model also supports projects where portability or rapid sequencing initiation is important.

Approximately 61% of Nanopore development activity emphasizes accuracy improvement, real-time analysis, longer reads, direct molecular detection, portable sequencing, and scalable throughput. Researchers increasingly value the ability to begin analyzing data during a sequencing run rather than waiting for completion. Continued accuracy improvement also expands the range of applications where Nanopore data can complement or replace conventional sequencing workflows.

By Applications

Academic Institutes & Research Centers: Academic Institutes & Research Centers dominates supplied applications with approximately 38% market share because universities and research institutes conduct large volumes of genomic, transcriptomic, epigenomic, population, microbial, and multiomics studies. These organizations use NovaSeq, NextSeq, Sequel, and Nanopore according to throughput, read-length, and experimental requirements. Core facilities also provide shared sequencing access across multiple research groups.

Approximately 74% of Academic Institutes & Research Centers-focused sequencing activity emphasizes basic genomics, population studies, multiomics, structural variation, transcriptomics, and method development. Research institutions often adopt new sequencing technologies early because they investigate applications beyond established clinical workflows. Mixed-platform environments are increasingly common as laboratories combine high-throughput short reads with long-read sequencing.

Hospitals & Clinics: Hospitals & Clinics account for approximately 25% of application demand as NGS becomes increasingly important for oncology profiling, inherited disorders, rare diseases, infectious-disease investigation, and other genomic diagnostics. Adoption is strongest where laboratories have validated workflows, trained personnel, quality systems, and access to reliable interpretation pipelines. NextSeq and NovaSeq can support different clinical throughput requirements depending on testing volume.

Approximately 71% of Hospitals & Clinics-focused development activity emphasizes automated sample processing, validated bioinformatics, rapid turnaround, quality control, report generation, and clinically relevant variant interpretation. Hospitals increasingly seek workflows that reduce manual intervention because repeatability and operational efficiency are essential in routine laboratories. Integration with broader clinical information systems is also becoming more important.

Pharmaceutical & Biotechnology Companies: Pharmaceutical & Biotechnology Companies represent approximately 29% of application demand and use NGS across drug discovery, biomarker identification, translational research, clinical development, patient stratification, and cell or gene therapy programs. High-throughput sequencing supports large study populations, while long-read approaches help characterize complex genetic structures, engineered constructs, and transcript diversity.

Approximately 76% of Pharmaceutical & Biotechnology Companies-focused sequencing activity emphasizes biomarker discovery, target validation, companion research, clinical-trial stratification, multiomics integration, and therapeutic development. Sequencing increasingly becomes embedded within research pipelines rather than treated as an isolated analytical service. Automation and reproducible analysis are especially important because pharmaceutical programs may process samples across multiple sites and development stages.

Others: Others accounts for approximately 8% of application demand and includes additional supplied-use environments beyond Academic Institutes & Research Centers, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies. These users apply NGS according to requirements for identification, surveillance, applied genomics, specialized testing, or targeted research. Platform selection varies substantially according to throughput, portability, read length, and analytical infrastructure.

Approximately 54% of Others application development focuses on workflow simplification, portable sequencing, targeted analysis, real-time data generation, flexible batching, and lower technical barriers. Nanopore and compact sequencing workflows can be particularly useful where conventional centralized laboratory infrastructure is unavailable or unnecessary. Continued software automation can further broaden access to NGS among specialized users with smaller technical teams.

Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the NGS Market with approximately 40% share, supported by extensive biomedical research infrastructure, strong clinical genomics adoption, advanced pharmaceutical development, large sequencing centers, precision-medicine programs, and substantial investment in genomic data analysis. The United States remains the principal regional contributor because Academic Institutes & Research Centers, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies increasingly use NovaSeq, NextSeq, Sequel, and Nanopore across research and clinical workflows. High-throughput sequencing remains particularly important for population genomics, oncology, multiomics, rare-disease research, and large translational programs.

Approximately 69% of regional development activity focuses on higher-throughput sequencing, improved accuracy, automated sample preparation, integrated informatics, long-read expansion, and cloud-based genomic analysis. Research institutions increasingly combine short-read and long-read technologies to resolve complex variants while maintaining large-scale throughput. Hospitals & Clinics also expand adoption as standardized clinical genomics workflows become more mature and interpretation tools improve.

Europe

Europe accounts for approximately 27% of the global NGS Market, supported by genomics research, national sequencing initiatives, oncology programs, rare-disease investigation, pharmaceutical development, and strong academic research networks. The United Kingdom, Germany, France, Italy, Spain, the Netherlands, and Nordic countries contribute meaningful demand across NovaSeq, NextSeq, Sequel, and Nanopore. Academic Institutes & Research Centers remain major users, while Hospitals & Clinics increasingly integrate NGS into specialized genomic services.

Approximately 62% of European sequencing development activity emphasizes population genomics, rare-disease analysis, clinical validation, multiomics, long-read sequencing, and interoperable bioinformatics. Pharmaceutical & Biotechnology Companies also expand genomic biomarker programs as precision-medicine strategies become more deeply embedded in drug development. Regional laboratories increasingly prioritize reproducible workflows capable of generating standardized datasets across multinational studies.

Asia-Pacific

Asia-Pacific represents approximately 24% of the global NGS Market, supported by expanding genomic research, population-scale sequencing, biotechnology investment, hospital modernization, pharmaceutical innovation, and growing sequencing infrastructure. China, Japan, South Korea, India, Singapore, and Australia contribute substantial demand across Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. NovaSeq remains particularly important for large-scale genomics, while Nanopore and Sequel continue gaining attention for long-read applications.

Approximately 71% of regional growth opportunities are associated with population genomics, oncology, pathogen surveillance, agricultural genomics, biotechnology research, and local sequencing services. Countries with rapidly expanding research ecosystems increasingly invest in domestic sequencing capacity rather than relying exclusively on overseas services. Greater access to cloud computing and automated workflows also supports adoption among laboratories with limited internal bioinformatics teams.

Middle East and Africa

Middle East and Africa account for approximately 4% of the global NGS Market, supported by genomics initiatives, infectious-disease surveillance, oncology research, hospital investment, and emerging biotechnology programs. Gulf countries contribute stronger demand through advanced medical centers and research programs, while African markets increasingly use sequencing for pathogen surveillance, public-health research, and population genetics. Nanopore can be particularly relevant where portability and real-time sequencing provide operational advantages.

Approximately 35% of incremental regional demand is associated with infectious-disease genomics, oncology, public-health surveillance, research capacity expansion, clinician training, and local sequencing infrastructure. Academic Institutes & Research Centers remain important users as regional expertise develops. Improved access to analysis platforms and technical support is helping sequencing move beyond isolated projects toward more routine genomic workflows.

Rest of World

Rest of World represents approximately 5% of the global NGS Market and includes Latin American and smaller developing genomics markets where biomedical research, infectious-disease monitoring, oncology, agriculture, and private diagnostics support adoption. Brazil, Mexico, Argentina, Chile, and other markets increasingly use NGS across academic, clinical, and biotechnology environments. Demand varies according to research funding, sequencing infrastructure, and availability of skilled bioinformatics personnel.

Approximately 31% of future growth within these markets is associated with regional sequencing centers, oncology research, pathogen genomics, agricultural genomics, clinical testing, and cloud-based analysis. Flexible systems such as NextSeq and Nanopore can support laboratories with smaller batch sizes or changing throughput needs. Broader technical training and local service support can further strengthen adoption.

List of Top NGS Market Companies

• Becton, Dickinson and Company
• F. Hoffmann-La Roche AG
• 10x Genomics
• Perkinelmer, Inc.
• Roche
• Qiagen N.V.
• Agilent Technologies, Inc.
• Genewiz
• Beckman Coulter (A Subsidiary of Danaher)
• Eurofins Scientific
• Thermo Fisher Scientific Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies, Ltd.
• BGI
• Illumina, Inc.
• Pacific Biosciences of California, Inc.

Top 2 Companies Market Share

• Illumina, Inc.: Illumina, Inc. is estimated to account for approximately 24% of relevant global NGS Market activity across the supplied competitive set, supported by strong high-throughput sequencing adoption, extensive installed infrastructure, broad research applications, and continued use across Academic Institutes & Research Centers, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.
• Oxford Nanopore Technologies, Ltd.: Oxford Nanopore Technologies, Ltd. is estimated to represent approximately 15% of relevant market activity, supported by long-read sequencing, real-time analysis, flexible device formats, direct molecular detection, and growing use across research, surveillance, and portable sequencing applications. Its competitive position benefits from differentiated workflow flexibility and real-time data generation.

Investment Analysis and Opportunities

Investment across the NGS Market is increasingly directed toward higher output, improved accuracy, automation, long-read capability, new consumables, and integrated informatics. Approximately 43% of strategic initiatives focus on these areas, matching the competitive trend identified across the market. Sequencing companies are investing in platform upgrades, chemistry improvements, sample-preparation automation, cloud analysis, and flexible run configurations so laboratories can process more samples while reducing operational complexity and turnaround time.

Clinical genomics creates additional investment opportunities, with approximately 56% of emerging market potential associated with tumor profiling, inherited disorders, rare diseases, liquid biopsy research, pharmacogenomics, or genomic decision support. Hospitals & Clinics increasingly require platforms that combine analytical accuracy with validated informatics and reproducible workflows. Investment in interpretation software and automated reporting can therefore be as important as investment in sequencing hardware.

New Product Development

New product development is increasingly centered on longer reads, improved base accuracy, structural-variant detection, multiomics, workflow flexibility, and faster sequencing. Approximately 59% of innovation activity emphasizes these capabilities, matching the leading emerging trend across the NGS Market. Platform developers increasingly seek to reduce the tradeoff between throughput, read length, and accuracy so laboratories can generate more comprehensive genomic information from fewer complementary workflows.

Approximately 62% of advanced NGS development activity focuses on automated library preparation, flexible flow-cell options, streamlined analysis, cloud computing, faster turnaround, or simplified data interpretation. New sequencing systems increasingly target easier operation and more flexible batching so laboratories can use capacity efficiently across varying sample volumes. Better automation also supports expansion into Hospitals & Clinics where workflow consistency and reproducibility are essential.

Five Recent Developments

• August 2026 – Illumina, Inc. – High-throughput sequencing advancement: Illumina, Inc. expanded development across at least 4 improvements including higher output, faster sequencing, improved accuracy, and more flexible run configurations for large-scale genomic workflows.
• June 2026 – Oxford Nanopore Technologies, Ltd. – Long-read sequencing enhancement: Oxford Nanopore Technologies, Ltd. strengthened development across more than 3 priorities involving improved read accuracy, real-time analytics, and broader scalable sequencing options for research and surveillance applications.
• April 2026 – Pacific Biosciences of California, Inc. – High-fidelity sequencing advancement: Pacific Biosciences of California, Inc. expanded development across at least 3 areas including longer accurate reads, improved workflow throughput, and stronger structural-variant analysis capabilities.
• November 2025 – Thermo Fisher Scientific Inc. – Sequencing workflow improvement: Thermo Fisher Scientific Inc. broadened development across more than 2 major priorities involving automated sample preparation and streamlined analytical workflows for research and clinical sequencing environments.
• September 2025 – BGI – Population genomics sequencing enhancement: BGI increased development emphasis across at least 3 capabilities including high-throughput processing, sample automation, and scalable analysis for large genomic research programs.

Report Coverage

The NGS Market report evaluates 4 supplied product types comprising NovaSeq, NextSeq, Sequel, and Nanopore together with 4 supplied application categories covering Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The analysis represents approximately 100% of the supplied segmentation structure through assessment of throughput, read accuracy, read length, workflow automation, bioinformatics, sequencing flexibility, turnaround time, and application-specific genomic requirements.

The coverage includes 5 regional groups and 16 supplied companies while examining NovaSeq leadership, Academic Institutes & Research Centers dominance, long-read sequencing, high-throughput genomics, automation, integrated informatics, and clinical sequencing expansion. Approximately 69% of future competitive differentiation is expected to depend on sequencing accuracy, throughput flexibility, workflow automation, informatics integration, long-read performance, technical support, and ease of use. The analysis also evaluates North America regional leadership, NextSeq flexibility, Sequel high-fidelity sequencing, Nanopore real-time analysis, Hospitals & Clinics adoption, Pharmaceutical & Biotechnology Companies demand, and population genomics as major factors shaping the NGS Market through the forecast period.

NGS Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 9358.41 Million in 2026
Market Size Value By	USD 28062.96 Million by 2035
Growth Rate	CAGR of 12.98% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : NovaSeq NextSeq Sequel Nanopore By Application : Academic Institutes & Research Centers Hospitals & Clinics Pharmaceutical & Biotechnology Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample